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1A4, CanAbstract: Cannabis is widely used as a self-management strategy by patients with a wide range of
symptoms and diseases including chronic non-cancer pain. The safety of cannabis use for medical
purposes has not been systematically evaluated. We conducted a prospective cohort study to
describe safety issues among individuals with chronic non-cancer pain. A standardized herbal
cannabis product (12.5% tetrahydrocannabinol) was dispensed to eligible individuals for a 1-year
period; controls were individuals with chronic pain from the same clinics who were not cannabis
users. The primary outcome consisted of serious adverse events and non-serious adverse events.
Secondary safety outcomes included pulmonary and neurocognitive function and standard
hematology, biochemistry, renal, liver, and endocrine function. Secondary efficacy parameters
included pain and other symptoms, mood, and quality of life. Two hundred and fifteen individuals
with chronic pain were recruited to the cannabis group (141 current users and 58 ex-users) and
216 controls (chronic pain but no current cannabis use) from 7 clinics across Canada. The median daily
cannabis dose was 2.5 g/d. There was no difference in risk of serious adverse events (adjusted
incidence rate ratio = 1.08, 95% confidence interval = .57–2.04) between groups. Medical cannabis
users were at increased risk of non-serious adverse events (adjusted incidence rate ratio = 1.73,
95% confidence interval = 1.41–2.13); most were mild to moderate. There were no differences in
secondary safety assessments. Quality-controlled herbal cannabis, when used by patients with
experience of cannabis use as part of a monitored treatment program over 1 year, appears to have
a reasonable safety profile. Longer-term monitoring for functional outcomes is needed.
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1234 The Journal of Pain Cannabis for the Management of PainPerspective: This study evaluated the safety of cannabis use by patients with chronic pain over 1
year. The study found that there was a higher rate of adverse events among cannabis users compared
with controls but not for serious adverse events at an average dose of 2.5 g herbal cannabis per day.
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he medical use of cannabis is an issue of major
public health importance. Several countries have
policies to allow patients to possess and use
cannabis for medical purposes. Recently, Health Canada
released the Marihuana for Medical Purposes Regula-
tions,8 which require a signed document from a health
professional for a patient to access cannabis for medical
purposes. A lack of data on the safety and efficacy of
cannabis is a major barrier to physicians’ involvement.
Several randomized controlled trials of smoked
cannabis have shown efficacy in chronic pain and
spasticity.1,4,17,18 These trials have been short
(1–3 weeks of exposure) with small sample sizes
(n = 20–60 participants). Several oral cannabinoid
prescription medications are available, and adverse
events from clinical trials of these compounds have
been reviewed16; some have been studied for periods
of up to 1 year.14,19 Given the potential health concerns
of recreational cannabis use,7 more safety data on the
long-term medical use of herbal cannabis are needed.
We conducted a multicenter cohort study to evaluate
safety issues in patients with chronic pain using cannabis
as part of their pain management regimen.Methods
Objectives
The primary objective was to assess the risk of adverse
events associated with cannabis when used in the treat-
ment of chronic pain. Secondary objectives were to
examine the effects of cannabis on pulmonary and neu-
rocognitive function, and to explore the effectiveness of
cannabis on chronic pain, including pain intensity and
quality of life.
Study Design
Aprospective cohort studywith a 1-year follow-upwas
conducted in 7 clinical centers across Canada between
January 2004 and April 2008.
Study Population
Patients 18 years of age or older were eligible if they
experienced chronic non-cancer pain for at least 6
months, with moderate to severe pain for which conven-
tional treatments had been considered medically inap-
propriate or inadequate. Patients using cannabis as part
of their treatment formed the cannabis group; those
who were not using cannabis formed the control group,
matched by site. We excluded patients who were preg-
nant or breast-feeding, who had a history of psychosis,
who exhibited significant and unstable ischemic heartdisease or arrhythmia, or who suffered from significant
and unstable bronchopulmonary disease. Patients were
instructed not to drive a car or operate a motor vehicle
while under the effects of cannabis. Written informed
consent was obtained from all participants.Study Drug
Herbal cannabis was provided by Prairie Plant Systems
Inc and contained 12.5 6 1.5% tetrahydrocannabinol
(THC) (see Supplementary Material S-1). Patients in the
cannabis group were able to use the delivery system
with which they were most comfortable. They were
advised to take the first dose in the evening, begin
with low doses, and titrate upward to the maximum
tolerated dose. An upper limit recommendation of
5 g/d was made to reduce the risk of diversion; higher
doses were allowed when deemed appropriate by the
prescribing physician. Cannabis was dispensed by the
site pharmacy at weekly intervals for the first month
and then monthly for the remainder of the study. Before
dispensing, patients returned unused cannabis for
weighing and destruction.Outcome Measures
Primary Outcome
The primary outcome of this studywas the incidence of
adverse events (AEs) as defined by the International Con-
ference onHarmonization.9 AEswere reported as serious
(SAEs) or non-serious using the International Conference
on Harmonization guidelines, and coded using the Med-
ical Dictionary for Regulatory Activities (MedDRAversion
11.0). Causality and severity were assessed by the study
physician using the World Health Organization-Uppsala
Monitoring Centre causality assessment system13 and
Common Terminology Criteria for Adverse Events v3.0.3
Serious and unexpected AEs were reported to Health
Canada and the institutional research ethics boards.
Secondary Outcomes
Neurocognitive function. Neurocognitive testing
comprised2 subtests of theWechslerMemoryScale—Third
Edition (Verbal Paired Associates I—Recall and Verbal
Paired Associates II, including recall and recognition) and
2 subtests of the Wechsler Adult Intelligence Scale—Third
Edition (Digit Symbol-Coding, Picture Arrangement).
Pulmonary function. Pulmonary function testing con-
sisted of slow vital capacity, functional residual capacity,
residual volume, total lung capacity, forced expiratory
volume in 1 second (FEV1), forced vital capacity (FVC),
Ware et al The Journal of Pain 1235and forced expired flow over the middle half of the vital
capacity (FEF25–75%).
Other safety parameters. Blood tests measured
hematological, biochemical, liver, kidney, and endocrine
function (prolactin, testosterone, thyroid-stimulating
hormone).
Efficacy measures. Pain intensity was measured using
visual analog scales (0, no pain; 10, worst pain possible)
as the average, highest, and lowest in the past 7 days,
and current pain intensity at the time of visit. Pain quality
was assessed using the McGill Pain Questionnaire, which
measures sensory, affective, and evaluative dimensions
of pain. Other symptomsweremeasured using themodi-
fied Edmonton Symptom Assessment Scale. Mood was
measured using the Profile of Mood States. Quality of
life was measured using the SF-36.Study Procedures
Baseline Assessment
All patients underwent baseline history and physical
examinations, addiction screening (Drug Abuse
Screening Test [DAST-20]), neurocognitive testing, and
urine drug testing (enzyme-linked immunosorbent
assay). Blood tests and pulmonary function tests were
conducted in the cannabis group only.
Follow-Up
Intended follow-up was for 1 year. Six clinical visits (1,
2, 3, 6, 9, and 12 months after baseline) and 3 telephone
interviews (1, 2, and 3weeks after the baseline visit) were
scheduled for patients in the cannabis group; 2 clinical
visits (6 and 12 months after baseline) and 5 telephone
interviews (1, 2, and 3 weeks, 3 and 9 months after base-
line) were scheduled for control patients.
Neurocognitive and efficacy assessments were con-
ducted at 6 and 12 months in all patients. Pulmonary
function tests were repeated in the cannabis group at
12 months. Blood tests were conducted in the cannabis
group at 1, 6, and 12 months. Patients were not specif-
ically instructed to abstain from cannabis use before
any study visits.
AE Reporting
AEs were captured during interviews at clinic visits,
during telephone contacts, or spontaneously by calling
the study nurse. At site visits, the studymonitor reviewed
patients’ hospital charts to ensure that serious events
were not missed.Sample Size and Power Considerations
For the primary outcome, the incidence of AEs among
cannabis users was compared with controls. It was
assumed that SAEs followed Poisson distributions in the
2 study groups. The intended sample size of this study
350 cannabis-using participants and 350 controls (see
Supplementary Materials S-3) meant that a rate ratio of
1.5 could be detected at powers above 60% for a control
group incidence rate of SAEs above .15 case/person-year,
and at a power above 70% for the incidence rate of SAEsin the control group above .20 case/person-year. These
estimates were derived from interim safety analyses dur-
ing a protocol revision (see SupplementaryMaterials S-3)
and are consistentwith estimates from ameta-analysis of
AEs from prescription cannabinoids.16Statistical Analysis
Primary Analysis
Demographic and clinical characteristics were
compared between the cannabis and control groups us-
ing parametric and non-parametric statistics as appro-
priate. Reasons for withdrawals were tabulated for
both groups. AEs were coded and tabulated using the
MedDRAheadings ‘‘systemorgan classes’’ and ‘‘preferred
terms.’’ AEs were characterized by severity, causality, and
outcome.
For incidence rate estimates, cumulative person-years
were calculated from the date of the baseline visit until
the date of discontinuation, death, or completion of
the study, whichever came first. The 95% confidence in-
tervals (CIs) for the rates were calculated using the Pois-
son distribution assumption.
An overdispersed Poisson regression model was used
to assess the occurrence of AEs among cannabis users
or controls.2,5,10 The results of the regression analyses
are presented as incidence rate ratios (IRRs) with
corresponding 95% CIs. Logistic regression analysis was
also performed to explore the association between the
risk of having at least 1 AE and medical cannabis use.
Odd ratios (ORs) with 95% CIs were calculated.
Subgroup Analysis
To further control for confounding by past cannabis
use, we estimated the stratified incidence rate of AEs
by past cannabis use in the cannabis and control groups.
We grouped past cannabis use into 3 categories. ‘‘Cur-
rent cannabis users’’ were those who reported using
cannabis at the baseline interview; ‘‘ex-cannabis users’’
were those who reported having previously used
cannabis but not at the baseline interview; ‘‘naive users’’
were those who reported never having used cannabis
before the baseline interview. We carried out a Poisson
regression analysis to explore whether the incidence
rate was consistent among participants with different
histories of cannabis use.
Secondary Analyses
A random effects model with a random intercept for
patient was used to model neurocognitive and pulmo-
nary function, pain,mood, symptom severity, and quality
of life. Age, gender, disability status, average pain inten-
sity, concomitant pain medication use, alcohol use (cur-
rent vs former or never users), tobacco use (current vs
former or never users), past cannabis use (ever vs never),
and study sites were incorporated as covariates.
Statistical analyses were undertaken with SAS soft-
ware (version 9.1; SAS Institute Inc, Cary, NC). No adjust-
ments for multiple comparisons were made.
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The original protocol was modified during the study
implementation to reduce the burden on the study par-
ticipants and aid recruitment. Details of these modifica-
tions are found in the Supplementary Materials (S-3).Ethics and Regulatory Approvals
The study was approved by the research ethics board
of each participating hospital and Health Canada. An in-
dependent Safety Monitoring Advisory Committee was
formed to ensure consistency for objectively and system-
atically categorizing the seriousness, severity, and causal-
ity of AEs (Supplementary Materials S-4).
Regulatory approval to use the herbal cannabis sup-
plied was obtained from the Therapeutic Products Direc-
torate of Health Canada.Results
From January 2004 to April 2008, 431 patients were re-
cruited, 215 in the cannabis group and 216 controls
(Fig 1). Median duration of follow-up was 11.9 months
(range = 7–551 days) in the cannabis group and
12.1 months (range = 28–567 days) in the control group
(outliers in follow-up time were due to late final visits;
Supplementary Table 1). The cannabis group included
141 (66%) ‘‘current cannabis users’’, 58 (27%) ‘‘ex-
cannabis users’’, and 16 (7%) ‘‘cannabis-naive users’’.
Controls included 70 (32%) ‘‘ex-cannabis users’’ and 146
(68%) ‘‘cannabis-naive users’’.Figure 1. COMPASS CONBaseline characteristics are presented in Table 1. Pa-
tients in the cannabis group were younger, with a
larger percentage of male, disabled, and tobacco or
alcohol users compared with the control group. Socio-
economic status did not differ between the groups.
The average pain intensity score at baseline was signif-
icantly higher in the cannabis group than in the control
group. Compared with cannabis users, more control pa-
tients were using opioids (55% in cannabis group vs
66% in the control group), antidepressants (47% vs
59%), or anticonvulsants (44% vs 55%) at baseline.
Three (1.4%) cannabis users reported ‘‘intermediate
severity’’ addiction problems as judged by the DAST-20
score.
Sixty-seven patients receiving study cannabis and 34
control patients discontinued the study before the full
year of follow-up; data from all patients were included
in the safety analysis.
There were no significant differences in baseline mea-
sures between patients who completed the study and
those who did not (Supplementary Table 2). However,
in the cannabis group, ‘‘cannabis-naive users’’ (9 [56%])
or ‘‘ex-cannabis users’’ (26 [45%]) were more likely to
withdraw from the study than ‘‘current cannabis users’’
(32 [23%]) (c2 [DF = 2] = 14.46, P < .001)
(Supplementary Table 2).
The median daily dosage among cannabis-using par-
ticipants was 2.5 g/d (range = .1–13.4; interquartile range
= 1.5–3.0); 11 (5%) patients received doses of >3 g/d.
Fifty-eight participants (27%) used smoking as the only
route of administration, 130 (61%) used a combinationSORT flow diagram.
Table 1. Baseline Characteristics of Study
Participants by Exposure Status
CHARACTERISTICS
CANNABIS GROUP
(N = 215)
CONTROL GROUP
(N = 216) P
Age at enrollment* 45.5 (19–82) 52.4 (21–83) <.001
Gender (% male)y 110 (51.2%) 76 (35.2%) <.001
Education
(% university/college)y
111 (51.6%) 122 (56.5%) .14
Married; n (%)y 133 (61.9%) 140 (64.8%) .52
Disabled; n (%)y 129 (60.0%) 102 (47.2%) .01
Tobacco statusyx .01
Current tobacco users 91 (42.3%) 67 (31.0%)
Ex-tobacco users 77 (35.8%) 73 (33.8%)
Never users 47 (21.9%) 76 (35.2%)
Alcohol statusy .05
Currently drinking 166 (77.2%) 149 (69.0%)
Not currently drinking 49 (22.8%) 67 (31.0%)
Past cannabis useyk <.001
Current cannabis users 141 (65.6%) 0
Ex-cannabis users 58 (27.0%) 70 (32.4%)
Naive users 16 (7.4%) 146 (67.6%)
Drug Abuse Screening Test{ <.0001
N/A (DAST = 0) 59 (27.4%) 133 (62.1%)
Low (DAST = 1–5) 153 (71.2%) 81 (37.9%)
Intermediate
(DAST = 6–10)
3 (1.4%) 0
Substantial
(DAST = 11–15)
0 0
Severe (DAST = 16–20) 0 0
Type of painy .40
Nociceptive 35 (16.3%) 39 (18.1%)
Neuropathic 83 (38.6%) 70 (32.4%)
Both 97 (45.1%) 107 (49.5%)
Average pain intensity* 6.6 (0–10) 6.1 (0–10) .002
Duration of pain (years)z 8.0 (0–54) 7.0 (0–82) .42
Medications
Opioidsy 118 (54.9%) 143 (66.2%) .02
Antidepressantsy 101 (47.0%) 128 (59.3%) .01
Anticonvulsantsy 94 (43.7%) 118 (54.6%) .02
*Mean (range), Student t-test.
yNumber of patients (proportion), c2.
zMedian (range), the Wilcoxon rank sum test.
x‘‘Current smokers’’ were those who reported smoking at the baseline interview;
‘‘ex-smokers’’ were those who reported abstinence from cigarettes at baseline;
‘‘never smokers’’ were those who reported never smoking at the baseline inter-
view.
k‘‘Current cannabis users’’ were those who reported using cannabis and were
still using at the baseline interview; ‘‘Ex-cannabis users’’ were those who re-
ported using cannabis but were not using at the baseline interview; ‘‘naive users’’
were those who reported never using cannabis before the baseline interview.
{Fisher’s exact test.
Ware et al The Journal of Pain 1237of smoking, oral, and vaporization, and 17 (8%)
consumed cannabis orally only (see Supplementary
Materials S-6; Supplementary Tables 3, 4, and 4a).AEs
SAEs
Twenty-eight (13%) patients in the cannabis group re-
ported at least 1 SAE, comparedwith 42 (19%) in the con-
trol group. The risk of having at least 1 SAE was not
significantly different between the 2 groups (unadjusted
OR = .64, 95% CI = .38–1.04). The total number of SAEswas similar in the cannabis and control groups (40 and
56, respectively). The incident rates of SAEs were 22.6
and 27.5 events per 100 person-years of follow-up in
the cannabis and control groups, respectively (unad-
justed IRR = .82, 95% CI = .46–1.46).
SAEs are shown in Table 2. The most common cate-
gories were ‘‘Surgical and medical procedures’’ and
‘‘Gastrointestinal disorders’’ (n = 10, 25%; n = 10, 25%,
respectively) in the cannabis group and (n = 11, 20%;
n = 7, 13%) in the control group (Supplementary
Table 5). The most common SAEs in the cannabis group
were abdominal pain (n = 3, 12%), intestinal obstruction
(n = 3, 12%), and nephrolithiasis (n = 3, 12%). None of
the SAEs was considered to be ‘‘certainly/very likely’’
related to study cannabis. One SAE (convulsion) was
considered ‘‘probably/likely’’ related to study cannabis.
Two participants in the control group died over the
course of the trial, 1 by suicide and the other died in
the operating room after emergency treatment for
abdominal pain; there were no deaths in the cannabis
group.
Treatment was stopped permanently for 2 patients
due to SAEs (1 convulsion and 1 alcohol problem). At
the end of the study, 31 (77.5%) of the SAEs in the
cannabis group had been fully resolved.Non-serious AEs
Most patients in the cannabis group (190 of 215;
88.4%) and the control group (184 of 216; 85.2%)
experienced at least 1 non-serious AE, with a median
of 3 events per participant (range = 0–16; interquartile
range = 2–5) among cannabis users and a median of 2
events per participant (range = 0–14, interquartile
range = 1–4) among controls. The risk of having at
least 1 AE did not differ significantly between cannabis
users and controls (unadjusted OR = 1.32, 95%
CI = .75–2.32).
A total of 818 non-serious AEs were reported in the
cannabis group, resulting in an incidence rate of 4.61
events/person-year. This rate was significantly higher
than in the control group in which there were 581 non-
serious AEs and an incidence rate of 2.85 events/
person-year (unadjusted IRR = 1.64, 95% CI = 1.35–1.99)
(Table 3).
The number of patients, the occurrence of events, and
corresponding rates within each MedDRA system organ
class category are shown in Table 3. The most common
AE categories in the cannabis groupwere nervous system
(n = 165, 20%), gastrointestinal (n = 109, 13.4%) and
respiratory disorders (n = 103, 12.6%). Compared with
controls, the rate of nervous system disorders
(unadjusted IRR = 2.05, 95% CI = 1.46, 2.86), respiratory
disorders (unadjusted IRR = 1.77, 95% CI = 1.16, 2.70), in-
fections disorder (unadjusted IRR = 1.51, 95% CI = 1.04,
2.20), and psychiatric disorders (unadjusted IRR = 2.74
95% CI = 1.45, 5.18) were significantly higher in the
cannabis group (Fig 2). Mild (420, 51.3%) or moderate
(390, 47.7%) events were more common than severe
events (8, 1.0%) in the cannabis group. Non-serious AEs
occurring more than once among cannabis users and
Table 2. SAEs Categorized by System Organ Class
SERIOUS AEs CANNABIS GROUP CONTROL GROUP
SYSTEM ORGAN CLASS (MEDDRA) NUMBER OF EVENTS RATE* NUMBER OF EVENTS RATE*
Surgical and medical procedures 10 5.65 11 5.39
Gastrointestinal disorders 10 5.65 7y 3.43
Musculoskeletal and connective tissue disorders 5 2.82 6 2.94
Injury, poisoning, and procedural complications 4 2.26 1 .49
Renal and urinary disorders 3 1.69 1 .49
Nervous system disorders 2 1.13 4 1.96
Respiratory, thoracic, and mediastinal disorders 1 .56 7 3.43
Infections and infestations 1 .56 5 2.45
Vascular disorders 1 .56 3 1.47
Metabolism and nutrition disorders 1 .56 2 .98
Psychiatric disorders 1 .56 2z .98
Investigations 1 .56 0 .00
General disorders and administration site conditions 0 .00 3 1.47
Blood and lymphatic system disorders 0 .00 1 .49
Eye disorders 0 .00 1 .49
Hepatobiliary disorders 0 .00 1 .49
Immune system disorders 0 .00 1 .49
Total 40 22.60x 56 27.45x
Total number of patients 28 13.02%k 42 19.44%k
*Unit: n/100 person-years.
yOne patient died in the operating room.
zOne patient committed suicide.
xThe rates of serious AEs did not differ significantly between these 2 groups (Unadjusted incidence rate ratio = .82, 95% CI = .46–1.46).
kThe risk of having reported at least 1 SAE was not significantly different between 2 groups (Unadjusted odds ratio = .62, 95% CI = .37–1.04).
1238 The Journal of Pain Cannabis for the Management of Painassessed as certainly/very likely related to cannabis were
somnolence (n = 5, .6%), amnesia (n = 4, .5%), cough
(n = 4, .5%), nausea (n = 4, .5%), dizziness (n = 3, .4%),
euphoric mood (n = 3, .4%), hyperhidrosis (n = 2, .2%),
and paranoia (n = 2, .2%) (Supplementary Table 7).
In the control group, gastrointestinal disorders
(n = 101, 17.4%) and nervous system disorders (n = 93,
16.0%) were the most frequently reported (Table 3).
The majority of AEs among controls were mild (57.3%)
or moderate (42.0%); 4 (.7%) were categorized as ‘‘se-
vere’’ (abdominal pain, breast cancer, pulmonary embo-
lism, and upper respiratory tract infection)
(Supplementary Tables 6–8).
Multiple Regression Analyses
The association between cannabis use and the rate of
AEs is summarized in Table 4. Medical cannabis users
had an increased risk of non-serious AEs (adjusted
IRR = 1.74, 95% CI = 1.42–2.14) but not SAEs (adjusted
IRR = 1.08, 95% CI = .57–2.04). Increasing the daily dose
of cannabis did not lead to higher risks of SAEs or AEs
(Supplementary Table 10).Neurocognitive Tests
Significant improvements were observed in all neuro-
cognitive subtests after 6 and 12 months in cannabis
users and controls (Table 5). After adjusting for age,
gender, education, alcohol history, disability status, con-
current average pain intensity, quality of life, and clinic
sites, no difference in neurocognitive function after 1
year was found between cannabis users and controls
(Supplementary Table 12).Pulmonary Function Tests
After adjusting for tobacco smoking and other covari-
ates, we did not find a significant change in slow vital ca-
pacity, functional residual capacity, and total lung
capacity over 1 year among the cannabis users. Residual
volume was reduced (mean reduction 142 mL), and a
mean decline of 54 mL in FEV1 and a mean decrease of
.78% in the FEV1/FVC ratio were noted. The FEF25–75%
was lower with a mean decrease of .2; no change was
observed in FVC (Supplementary Tables 13 and 14).
Blood Tests
Seventy-eight patients in the cannabis group had
blood tests conducted at baseline and at 1 year. No
changes in liver, renal, and endocrine function were
observed (Supplementary Tables 15 and 16).
Efficacy Measures
Pain Intensity
Compared with baseline, a significant reduction in
average pain intensity over 1 year was observed in the
cannabis group (change = .92; 95% CI = .62–1.23) but
not in the control group (change = .18; 95% CI = .13
to .49). After adjusting for confounders, a greater reduc-
tion in pain was observed among cannabis users than
among controls (difference = 1.10, 95% CI = .72–1.56)
(Fig 3; Supplementary Tables 17 and 18).
Quality of Life
With regard to the change in Physical Component
Summary (PCS) score, a significant improvement from
Table 3. Summary of Non-serious AEs Categorized by System Organ Class
NON-SERIOUS AEs CANNABIS GROUP CONTROL GROUP
SYSTEM ORGAN CLASS (MEDDRA)
NUMBER OF
PERSONS
REPORTING
SYMPTOMS
NUMBER OF
EVENTS
REPORTED
RATE (EVENTS/
PERSON-YEAR)
NUMBER OF
PERSONS
REPORTING
SYMPTOMS
NUMBER OF
EVENTS
REPORTED
RATE (EVENTS/
PERSON-YEAR)
Nervous system disorders 101 165 .93 71 93 .46
Gastrointestinal disorders 66 109 .62 70 101 .50
Respiratory, thoracic, and mediastinal disorders 77 103 .58 49 67 .33
Infections and infestations 63 89 .50 49 68 .33
Musculoskeletal and connective tissue disorders 49 77 .44 50 67 .33
Psychiatric disorders 47 57 .32 21 24 .12
General disorders and administration site conditions 29 35 .20 20 23 .11
Injury, poisoning, and procedural complications 23 31 .18 21 23 .11
Renal and urinary disorders 23 29 .16 18 22 .11
Skin and subcutaneous tissue disorders 18 22 .12 17 18 .09
Investigations 21 21 .12 8 8 .04
Eye disorders 16 20 .11 13 14 .07
Reproductive system and breast disorders 11 15 .08 5 6 .03
Metabolism and nutrition disorders 14 14 .08 7 7 .03
Vascular disorders 8 8 .05 9 9 .04
Surgical and medical procedures 6 7 .04 10 12 .06
Cardiac disorders 4 4 .02 7 7 .03
Blood and lymphatic system disorders 4 4 .02 0 0 .00
Ear and labyrinth disorders 3 3 .02 5 5 .02
Immune system disorders 1 2 .01 3 3 .01
Hepatobiliary disorders 2 2 .01 1 1 .00
Endocrine disorders 1 1 .01 0 0 .00
Neoplasms benign, malignant, and unspecified
(including cysts and polyps)
0 0 .00 3 3 .01
Total 191 818 4.62 186 581 2.85
Unadjusted OR (95% CI) 1.28 (.72–2.28) 1
Unadjusted IRR (95% CI) 1.62 (1.34–1.97) 1
Ware et al The Journal of Pain 1239baseline was observed in both groups at the 6- and
12-month clinic visits. Analysis of the change in the PCS
indicated greater improvement of physical function in
cannabis users than in controls (2.36 point greaterFigure 2. Unadjusted incidence rate ratios of nonimprovement at 6 months, 95% CI = .84–3.88; and 1.62
points at 1 year, 95% CI = .10–3.14). No within-group or
between-group differences for the Mental Component
Summary were observed (Supplementary Table 25).-serious adverse events by system organ class.
Table 4. Unadjusted and Adjusted Rate Ratios of AEs for Medical Cannabis
CANNABIS CONTROL UNADJUSTED IRR (95% CI) ADJUSTED IRR* (95% CI)
All patients
Number of patients 215 216 – –
Cumulative person-years 176.9 204.1 – –
Number of SAEs 40 56 .82 (.46–1.46) 1.08 (.57–2.04)
Number of AEs 818 574 1.64 (1.35–1.99) 1.74 (1.42–2.14)
Patients excluding ‘‘current cannabis users’’y at baseline
Number of patients 74 216 – –
Cumulative person-years 52.2 204.1 – –
Number of SAEs 20 56 1.40 (.66–2.93) 1.77 (.72–4.32)
Number of AEs 316 574 2.15 (1.69–2.74) 2.07 (1.59–2.70)
*Adjusted for age at enrollment, gender, baseline pain intensity, baseline concomitant pain medication (yes/no), disability status (yes/no), tobacco use (current vs former
or never smokers), alcohol use (current vs former or never users), past cannabis use (ever/never), and study sites.
y‘‘Current cannabis users’’ were those who reported using cannabis and were still using at the baseline interview.
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The sensory component of painwas reducedover 1 year
in cannabis users comparedwith controls (Supplementary
Tables 19 and 20). The total symptom distress score of the
Edmonton Symptom Assessment Scale was also improved
in cannabis users over 1 year (Supplementary Tables 21
and 22). The total mood disturbance scale of the Profile
of Mood States showed significant improvement for
cannabis users compared with controls, with
improvements found in the tension-anxiety, depression-
dejection, anger-hostility, and fatigue-inertia subscales
(Supplementary Tables 23 and 24).
Discussion
To our knowledge, this is the first cohort study of the
long-term safety of medical cannabis use ever conduct-
ed. Over 1 year, we identified 40 SAEs among 28 patients,
and 818 non-serious AEs among 190 patients using med-
ical cannabis. Headache, nasopharyngitis, nausea, som-
nolence, and dizziness were the most common AEs
reported. Medical cannabis use did not increase the risk
of SAEs compared with controls but was associatedTable 5. Neurocognitive Measures in Cannabis-Exp
GROUP NUMBER OF
WMS-III y
Verbal paired associates I
Recall (max 32 points) Cannabis 77
Control 53
Verbal paired associates II
Recall (max 8 points) Cannabis 76
Control 53
Recognition (max 24 points) Cannabis 76
Control 53
WAIS-III z
Digit symbol-coding (max 133 points) Cannabis 72
Control 53
Picture arrangement (max 22 points) Cannabis 76
Control 53
*Data are presented as mean (SD).
yWMS-III, Wechsler Memory Scale, Third Edition.
zWAIS-III: Wechsler Adult Intelligence Scale, Third Edition.with an increased risk of non-serious AEs, particularly
with respect to nervous system and psychiatric disorders.
This adverse event profile is similar to pharmaceutical
cannabinoids.16
We found 78 respiratory events in the cannabis group
and 56 in the control group, and most were considered
mild or moderate. No increase in risk of serious respira-
tory AEs associated with medical cannabis use was
detected (1 SAE in the cannabis group, and 7 in the con-
trol group). Medical cannabis users had a higher rate of
developing non-serious respiratory AEs during 1 year of
follow-up compared with controls. This is consistent
with reports that long-term cannabis smoking is associ-
ated with an increased risk of chronic bronchitis.12 In
our study, cannabis users had a mean 50-mL decrease in
FEV1 and a mean 1% decrease in the FEV1/FVC ratio
over 1 year.
Neurocognitive function improved in both groups.
This finding differs from that found in recreational
users of cannabis; a meta-analysis of 15 studies investi-
gating the effects of recreational cannabis use on neu-
rocognitive performance6 suggested that long-term
cannabis users performed significantly poorer on testsosed and Control Individuals Over 1 Year*
PATIENTS BASELINE 6 MONTHS 12 MONTHS
16.92 (7.69) 20.97 (8.01) 22.97 (7.56)
17.42 (7.85) 19.25 (8.70) 22.72 (8.53)
5.67 (2.35) 6.29 (2.05) 6.54 (1.81)
5.45 (2.55) 6.02 (2.45) 6.64 (1.95)
23.80 (.80) 23.92 (.32) 23.78 (1.41)
23.94 (.23) 23.98 (.14) 23.98 (.14)
52.21 (21.60) 53.31 (23.64) 55.90 (23.11)
49.94 (18.82) 54.64 (20.26) 55.00 (17.65)
11.64 (3.91) 13.67 (5.03) 14.18 (4.36)
11.42 (4.65) 13.32 (5.14) 14.24 (5.53)
Figure 3. Changes in pain intensity over 1 year (data only shown for patients with complete data at all time points; n = 145
(cannabis), n = 157 (controls). Abbreviation: VAS, visual analog scale.
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that study, both groups consumed similar amounts of
cannabis (median = 7 g/wk, range = .3–57 g/wk), and
there was no difference in memory and attention be-
tween short-term users and non-cannabis users.
Longer-term follow-up of the neurocognitive effects
of medical cannabis use is needed.
We found no impact of medical cannabis use on mea-
sures of hematological, biochemical, liver, renal, and
endocrine function among 78 patients followed over 1
year.
With respect to secondary efficacy measures, we noted
significant improvements in pain intensity and the phys-
ical dimension of quality of life over 1 year among the
cannabis users compared with controls; there was also
significant improvement among cannabis users in mea-
sures of the sensory component of pain, symptom
distress, and total mood disturbance comparedwith con-
trols. These findings, although not the primary outcomes
of the study, are nevertheless important in considering
the overall risk-benefit ratio of medical use of cannabis.
There are several limitations of our study. First, the
relatively small sample size and short follow-up time pre-
vented our study from identifying rare SAEs. Following
215 patients (177 person-years) in the cannabis group
and 216 (204 person-years) in the control group enabled
us to detect a rate ratio of 1.5 at powers above 50% for
an incidence rate of SAEs in the control group above
.20 case/person-year.
Second, we observed a significant drop-out rate,
which may be a source of selection bias. Losses to
follow-up were estimated at 30% over a median
follow-up of 12 months. Factors associated with drop-
out included AEs, perceived lack of efficacy, and/or a
dislike of the study product. However, patients lost tofollow-up were comparable with patients who finished
the entire study.
Third, most study participants in the cannabis group
(66%) were experienced cannabis users. Due to the small
number of cannabis-naive patients in the study, the
safety of medical cannabis use in cannabis-naive individ-
uals cannot be addressed. Moreover, our results indicate
that the rate of non-serious AEs among ‘‘current
cannabis users’’ was lower than that among ‘‘ex-cannabis
users’’ or ‘‘naive users.’’ We would likely have observed a
higher rate of AEs for cannabis if only new cannabis users
had been included.
Fourth, observational bias could come from ascertain-
ment of outcomes. Given the difference in follow-up (9
visits after baseline in the cannabis group vs 7 in the con-
trol group), patients in the cannabis group may have re-
ported AEs otherwise neglected by controls. The effect
of this limitation is likely to lead tomore exaggerated es-
timates of AEs among medical cannabis users than
among the controls.
Fifth, confounding by indication due to selective pre-
scribing is another potential source of bias.15 This bias
may exist in our study because herbal cannabis was
authorized for refractory patients who had more pain
and disability than controls. Information on determi-
nants of prescription choices was unmeasured, but
pain intensity and disability were considered as the
most important factors influencing the decision to use
medical cannabis. Adjusting for these 2 variables in
the final model of our study helped to control indica-
tion bias.
With respect to the observed improvements in second-
ary efficacy measures, we interpret these with caution
because the study was not a randomized controlled trial
and allocation was not blinded. It is possible that
1242 The Journal of Pain Cannabis for the Management of Painimprovements in these efficacy measures resulted from
regression to the mean, natural history of disease or
the effect of being in the study. However, these biases
would apply to both groups, yet still we noted difference
between groups.
Despite these limitations, this study improves our
knowledge about the safety of medical cannabis.
Caution should be exercised in interpreting these results
for all medical cannabis use as patients in this study used
a standardized, quality-controlled herbal cannabis prod-
uct with a reliable THC potency of 12.5%.
In conclusion, this study suggests that the AEs of
medical cannabis are modest and comparable quanti-
tatively and qualitatively with prescription cannabi-
noids. The results suggest that cannabis at average
doses of 2.5 g/d in current cannabis users may be
safe as part of a carefully monitored pain manage-
ment program when conventional treatments have
been considered medically inappropriate or inade-
quate. However, safety concerns in naive users
cannot be addressed. Moreover, long-term effects
on pulmonary functions and neurocognitive func-
tions beyond 1 year cannot be determined. Further
studies with systematic follow-up are required to
characterize safety issues among new cannabis usersand should be extended to allow estimation of
longer-term risks.
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